Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (234) Apply Press releases filter
- Basic page (60) Apply Basic page filter
- Corporate presentations (26) Apply Corporate presentations filter
- Pipeline (26) Apply Pipeline filter
- Shareholder meeting (24) Apply Shareholder meeting filter
- Team member (21) Apply Team member filter
- Videos (16) Apply Videos filter
- Analyst (12) Apply Analyst filter
- Financial reports (12) Apply Financial reports filter
- Webcasts and audio (12) Apply Webcasts and audio filter
- Investor contact (6) Apply Investor contact filter
- Event (3) Apply Event filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
John Dawson to retire from Oxford Biomedica
Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene a
Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease
- Negligible financial impact on Oxford Biomedica in the short and medium term
CAR-T (Arcellx)
This is a partner product. Visit the relevant partner website for further information.
Adeno-Associated Virus (AAV) platform
Our experienced team of end-to-end AAV experts strive to accelerate progress in the AAV industry to further our mission to improve patients
All platforms
Oxford Biomedica is a global cell and gene therapy company with capabilities across key viral vector types and a focus on
Adenovirus expertise
Building on its world leading position in lentiviral vectors, Oxford Biomedica has demonstrated the versatility of its platform by undertak